1. Pink Sheet
  2. >>Product Reviews

Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic

 
• By Bridget Silverman

The latest news about novel agent applications from our FDA Performance Tracker.

Keeping Track Feature image

The first product candidates to emerge from two high-profile spaces, a new class for migraine and a gene therapy, are under review at FDA after a busy week for novel agent submissions.

FDA also filed a new drug application (NDA) for a new oncologic and a botulinum toxin for cosmetic use. (For more information on applications under review at FDA, see the FDA Performance Tracker's User Fee Goal Dates chart

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman

The US FDA seeks advice on the clinical meaningfulness of the endpoints of J&J’s AQUILA trial in smoldering multiple myeloma, highlighting the pitfalls of being the first candidate for the precancerous condition.

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.